newsfilter
← Latest News
Earnings Call Transcripts·

Danon Disease Program Update: RP-A501 Pivotal Phase 2 Trial - ROCKET PHARMACEUTICALS INC

Good day, and welcome to the Rocket Pharmaceuticals Investor Program Update on Dana Disease and the RPA501 Pivotal Phase II Trial. As a reminder, today's program is being recorded. I will now turn the program over to Meg

Company
ROCKET PHARMACEUTICALS INC
Keywords
ROCKET PHARMACEUTICALS INC